Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12587156 | 0.83 | TRPA1 (0.41) | TRPA1 | |
| SCHEMBL13916921 | 0.83 | TRPA1 (0.41) | TRPA1 | |
| SCHEMBL12284775 | 0.81 | TSHR (0.39) | TRPA1 | |
| SCHEMBL12503470 | 0.80 | GRIN1 (0.33) | TRPA1 | |
| SCHEMBL8466135 | 0.79 | TRPA1 (0.36) | TRPA1 | |
| SCHEMBL8454747 | 0.79 | ESR2 (0.32) | TRPA1 | |
| SCHEMBL17019835 | 0.78 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL9977661 | 0.78 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL16845038 | 0.78 | LMNA (0.37) | — | |
| SCHEMBL8482393 | 0.78 | SIGMAR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273067-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2015126737-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20150232481-A1 | Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232481-A1 | Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | TYMP, EIF2AK2, MAVS | TRPA1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.